PortfoliosLab logo
DGX vs. JNJ
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between DGX and JNJ is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

DGX vs. JNJ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Quest Diagnostics Incorporated (DGX) and Johnson & Johnson (JNJ). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

DGX:

1.22

JNJ:

0.07

Sortino Ratio

DGX:

2.12

JNJ:

0.28

Omega Ratio

DGX:

1.26

JNJ:

1.04

Calmar Ratio

DGX:

1.75

JNJ:

0.13

Martin Ratio

DGX:

7.89

JNJ:

0.35

Ulcer Index

DGX:

3.66%

JNJ:

6.43%

Daily Std Dev

DGX:

21.90%

JNJ:

19.02%

Max Drawdown

DGX:

-49.46%

JNJ:

-52.60%

Current Drawdown

DGX:

-2.25%

JNJ:

-12.81%

Fundamentals

Market Cap

DGX:

$19.64B

JNJ:

$370.87B

EPS

DGX:

$7.91

JNJ:

$8.99

PE Ratio

DGX:

22.24

JNJ:

17.15

PEG Ratio

DGX:

1.57

JNJ:

1.07

PS Ratio

DGX:

1.93

JNJ:

4.15

PB Ratio

DGX:

2.85

JNJ:

4.85

Total Revenue (TTM)

DGX:

$10.16B

JNJ:

$89.33B

Gross Profit (TTM)

DGX:

$3.31B

JNJ:

$61.01B

EBITDA (TTM)

DGX:

$1.95B

JNJ:

$34.70B

Returns By Period

In the year-to-date period, DGX achieves a 16.80% return, which is significantly higher than JNJ's 3.46% return. Over the past 10 years, DGX has outperformed JNJ with an annualized return of 11.65%, while JNJ has yielded a comparatively lower 6.73% annualized return.


DGX

YTD

16.80%

1M

6.40%

6M

8.97%

1Y

26.46%

5Y*

11.92%

10Y*

11.65%

JNJ

YTD

3.46%

1M

-2.17%

6M

-1.19%

1Y

1.31%

5Y*

2.97%

10Y*

6.73%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

DGX vs. JNJ — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DGX
The Risk-Adjusted Performance Rank of DGX is 8989
Overall Rank
The Sharpe Ratio Rank of DGX is 8888
Sharpe Ratio Rank
The Sortino Ratio Rank of DGX is 8787
Sortino Ratio Rank
The Omega Ratio Rank of DGX is 8484
Omega Ratio Rank
The Calmar Ratio Rank of DGX is 9292
Calmar Ratio Rank
The Martin Ratio Rank of DGX is 9292
Martin Ratio Rank

JNJ
The Risk-Adjusted Performance Rank of JNJ is 5151
Overall Rank
The Sharpe Ratio Rank of JNJ is 5454
Sharpe Ratio Rank
The Sortino Ratio Rank of JNJ is 4343
Sortino Ratio Rank
The Omega Ratio Rank of JNJ is 4444
Omega Ratio Rank
The Calmar Ratio Rank of JNJ is 5757
Calmar Ratio Rank
The Martin Ratio Rank of JNJ is 5555
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

DGX vs. JNJ - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Quest Diagnostics Incorporated (DGX) and Johnson & Johnson (JNJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current DGX Sharpe Ratio is 1.22, which is higher than the JNJ Sharpe Ratio of 0.07. The chart below compares the historical Sharpe Ratios of DGX and JNJ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Dividends

DGX vs. JNJ - Dividend Comparison

DGX's dividend yield for the trailing twelve months is around 1.75%, less than JNJ's 3.34% yield.


TTM20242023202220212020201920182017201620152014
DGX
Quest Diagnostics Incorporated
1.75%1.96%2.02%2.08%1.40%1.85%1.99%2.34%1.83%1.72%2.07%1.92%
JNJ
Johnson & Johnson
3.34%3.40%3.00%2.52%2.45%2.53%2.57%2.74%2.38%2.73%2.87%2.64%

Drawdowns

DGX vs. JNJ - Drawdown Comparison

The maximum DGX drawdown since its inception was -49.46%, smaller than the maximum JNJ drawdown of -52.60%. Use the drawdown chart below to compare losses from any high point for DGX and JNJ. For additional features, visit the drawdowns tool.


Loading data...

Volatility

DGX vs. JNJ - Volatility Comparison

Quest Diagnostics Incorporated (DGX) has a higher volatility of 8.04% compared to Johnson & Johnson (JNJ) at 5.99%. This indicates that DGX's price experiences larger fluctuations and is considered to be riskier than JNJ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

DGX vs. JNJ - Financials Comparison

This section allows you to compare key financial metrics between Quest Diagnostics Incorporated and Johnson & Johnson. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20.00B25.00B20212022202320242025
2.65B
21.89B
(DGX) Total Revenue
(JNJ) Total Revenue
Values in USD except per share items

DGX vs. JNJ - Profitability Comparison

The chart below illustrates the profitability comparison between Quest Diagnostics Incorporated and Johnson & Johnson over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

30.0%40.0%50.0%60.0%70.0%20212022202320242025
32.5%
66.4%
(DGX) Gross Margin
(JNJ) Gross Margin
DGX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Quest Diagnostics Incorporated reported a gross profit of 863.00M and revenue of 2.65B. Therefore, the gross margin over that period was 32.5%.

JNJ - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Johnson & Johnson reported a gross profit of 14.54B and revenue of 21.89B. Therefore, the gross margin over that period was 66.4%.

DGX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Quest Diagnostics Incorporated reported an operating income of 346.00M and revenue of 2.65B, resulting in an operating margin of 13.1%.

JNJ - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Johnson & Johnson reported an operating income of 6.30B and revenue of 21.89B, resulting in an operating margin of 28.8%.

DGX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Quest Diagnostics Incorporated reported a net income of 220.00M and revenue of 2.65B, resulting in a net margin of 8.3%.

JNJ - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Johnson & Johnson reported a net income of 11.00B and revenue of 21.89B, resulting in a net margin of 50.2%.